paired Cl
− conductance, Na + hyperabsorption, mucus hypersecretion, and impaired mucociliary clearance in CF airways (2) . CF airway epithelial cells produce the proinflammatory cytokine interleukin (IL)-8 that strongly regulates the neutrophil-dominated inflammatory process characteristic of CF airways (2, 3) and have led to numerous studies evaluating the mechanisms underlying IL-8 induction in CF airways.
IL-17A is a cytokine that was recently shown to be primarily produced by a CD4 + T cell subset, T helper 17 (Th17) cells (4) , and a critical factor in the protection of the host during infection with extracellular pathogens such as Citrobacter rodentium (5) , Staphylococcus aureus (5) , Klebsiella pneumoniae (6) , and Candida albicans (7) . In addition to its protective role in host defense, IL-17A has also been associated with promoting the autoimmune response causing diseases like rheumatoid arthritis (RA), multiple sclerosis (MS), and inflammatory bowel disease (IBD) (8) . Moreover, IL-17A has also been implicated in inflammation associated with chronic inflammatory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and CF (8 -10) . In each scenario, direct up-regulation of downstream target genes as well as exaggerated cytokines or infectious signals by IL-17A seem to play a critical role in the progression of the disease (8, 11, 12) .
Toll-like receptors (TLRs) are type I transmembrane receptors that directly interact with pathogen-associated molecular patterns (PAMPs) on a variety of bacteria and activate signaling pathways, which plays an important role in innate immune recognition of the invading bacteria (13, 14) . Among the TLRs, TLR2 and TLR4 have gained prominence as receptors for bacterial peptidoglycan (PGN) and lipopolysaccharide (LPS), respectively (15, 16) . Despite the importance of optimal TLR2 and TLR4 signals during the innate immune response, enhanced signal transduction, expression, and overproduction of inflammatory cytokines lead to inflammatory disease states. Importantly, a number of groups, including our own, have demonstrated increased proinflammatory responses towards TLR2 and TLR4 ligands that contribute to the IL-8-associated CF pathogenesis in CF airways (17 -20) .
Recently, increased expression of IL-17A was shown in bronchoalveolar lavage (BAL) fluid and sputum from bacterially infected CF patients (21, 22) . Moreover, Roussel et al. (23) showed that IL-17A enhances P. aeruginosa filtrate (PAF)-induced IL-8 induction in the CuFi CF airway epithelial cell line apparently through the up-regulation of a NOD-like receptor (NLR) family protein, nucleotide-binding oligomerization domain 1 (NOD1). These studies suggest that IL-17A may contribute to IL-8-dependent CF pathogenesis. In the present study, the effect of IL-17A stimulation on the CF airway epithelial cell response to two major bacterial components, Gram-positive bacterial PGN, a TLR2 agonist, and Gram-negative bacterial LPS, a TLR4 agonist, was evaluated to further understand the physiological relevance of IL-17A in CF pathogenesis. The studies showed a strong synergism between IL-17 and TLR2 and TLR4 induction of IL-8 expression in a CF airway epithelial cell line and in primary patient-derived CF primary bronchial epithelial cells. The IL-17A-dependent synergy appeared to be the result of enhanced PGN-or LPS-induced phosphorylation of p38 MAPK. Overall, the data suggest that IL-17A is a critical factor in increasing IL-8 expression in bacteria-infected CF airway, possibly via a pathway that regulates p38 MAPK phosphorylation.
Materials and Methods

Reagents and antibodies
Recombinant human IL-17A was purchased from R&D Systems (Minneapolis, MN, USA). LPS (from E. coli 0111:B4), SB203580, and actinomycin D were purchased from Sigma (St. Louis, MO, USA). SP600125 was purchased from Biomol (Plymouth Meeting, PA, USA). PGN from Staphylococcus aureus was purchased from Fluka (Buchs, Switzerland). PD98059 and anisomycin were purchased from Calbiochem (La Jolla, CA, USA). Anti-phospho-JNK (Thr183/Tyr185), antiphospho-p38 (Thr180/Tyr182), anti-phospho-ERK1/2 (Thr202/Tyr204), and anti-phospho IκBα (Ser32) antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA). Anti-actin antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Cell culture and treatment
16HBE14o- (24) and CFBE41o-(25) cells were generated as described previously and grown in a fibronectin/ vitrogen/BSA-coated flask in MEM (19) . CFBE41o-is a well-characterized cell line that was generated by transformation of CF tracheo-bronchial cells with SV40 and was reported to be homozygous for the ΔF508 mutation (ΔF508/ΔF508). Because CFBE41o-cells retain many aspects of human CF bronchial epithelial cells, it is mainly used in this study. Calu-3 cells were purchased from ATCC (Manassas, VA, USA) and cultured in DMEM/F12 (26) . All cell lines were cultured in the medium supplemented with 10% FBS, 100 U/ml of penicillin, and 100 μg/ml of streptomycin. Primary normal (NHBE) and primary diseased human bronchial epithelial cells derived from a patient CF (DHBE-CF) were purchased from Takara Biomedical Co. (Otsu) and were maintained in BEBM supplemented with BEGM SingleQuots including Bovine Pituitary Extract, insulin, hydrocortisone, GA-1000, retinoic acid, transferrin, triiodothyronine, epinephrine, and human epidermal growth factor (Takara Biomedical Co.) according to the manufacturer's instruction. All cells were cultured in a humidified atmosphere of 5% CO 2 in air at 37°C. For the detection of IL-8 induction, all cell lines were subjected to serum starvation 12 h prior to the treatment with PGN or LPS to reduce the background activation of IL-8 expression, while primary cells were cultured in BEBM containing only insulin, GA-1000, transferrin, and triiodothyronine 12 h prior to the treatment with PGN or LPS.
Quantitative real-time RT-PCR analysis
Quantitative real-time RT-PCR for human IL-8, TLR2, TLR4, and 18s ribosomal RNA (18srRNA) was carried out using the primers shown in Table 1 as previously described (27) . Briefly, total RNA from the cells was isolated using RNAisoPlus and synthesis of cDNA was performed using PrimeScript RT regent kit (Takara Biomedical Co.). Real-time quantitative RT-PCR analysis was performed using SYBR Premix Ex Taq (Takara Biomedical Co.). The relative quantity of target genes' mRNA was normalized using 18srRNA as the internal control and expressed as the relative quantity of target genes' mRNA (fold induction).
SDS-PAGE and western blotting
Cells grown to 90% -100% confluence on 6-cm plates were used to collect the cell protein lysates. The protein lysates were analyzed by SDS-PAGE and western blotting as described previously (28) .
ELISA analysis
The IL-8 concentration in the culture supernatant was assessed by an ELISA kit for human IL-8 (CXCL8/IL-8 Duo Set) from R&D Systems (Minneapolis, MN, USA) according to the manufacturer's instruction. Briefly, 100 μl of sample was added to each well coated with a murine monoclonal antibody against IL-8. To be within range, supernatants from cell cultures were optimally diluted in serum-free medium. A biotinylated goat anti-human IL-8 was added, and samples were incubated for 2 h, followed by the incubation with a streptavidin conjugated to horseradish-peroxidase. After three washes between each step, substrate solution was added for 20 min. Absorbance was measured on a microplate reader at 450 nm, and IL-8 concentration was determined in each sample by comparison to a standard curve.
Statistical analysis
The data were analyzed by one-way ANOVA with the Tukey-Kramer multiple comparison test (JMP software; SAS Institute, Cary, NC, USA) as indicated in each figure legend.
Results
IL-17A-dependent IL-8 induction in human CFBE41o-cells
To confirm the effect of IL-17A on the regulation of IL-8 gene expression in CF airways, CFBE41o-cells were first treated with IL-17A and the IL-8 mRNA levels were assessed by quantitative real-time RT-PCR. As shown in Fig. 1A , after the treatment with IL-17A, the IL-8 mRNA expression in CFBE41o-cells was slightly but significantly up-regulated. A significant increase in IL-8 gene expression was observed at IL-17A concentrations in the range 10 -100 ng/ml. IL-17A-dependent up-regulation of IL-8 protein was also observed by ELISA (Fig. 1B) . To further elucidate the signaling pathways involved in IL-8 up-regulation, NF-κB activation and the MAPKs signaling pathways in CFBE41o-cells were assayed because they are downstream signals of IL-17A activation in numerous cell types (8) . Exposure to IL-17A results in phosphorylation of the JNK, p38, and ERK pathways (Fig. 1C ), but not in IκBα, an activator of NF-κB. The role of these MAPK signaling pathways in the regulation of IL-17A-dependent IL-8 induction in CFBE41o-cells was elucidated with specific inhibitors of JNK, p38, and ERK pathways. SB203580 and PD98059, but not SP600125, significantly suppressed IL-17A-dependent IL-8 induction (Fig. 1D ). These data suggest that p38 and ERK affect the IL-17A-dependent signaling pathway for the IL-8 induction in 
IL-17A synergizes with PGN and LPS to promote IL-8 induction in human CF airway epithelial cell lines and primary cells
Since IL-17A has been shown to affect other signaling pathways (11), the modulatory role of IL-17A in signaling during bacterial infection in CF airways. The effect of co-treatment with IL-17A and Gram-positive bacterial PGN was initially assayed. PGN, a TLR2 agonist, alone up-regulates IL-8 in CFBE41o-cells (Fig. 2: A and B) . There was a notable synergy in the induction of IL-8 gene and protein expressions when PGN was used in combination with IL-17A (Fig. 2: A and B) . Similar analyses performed using non-CF airway epithelial cell lines, 16HBE14o-and Calu-3 cells, showed no synergism with the combination of IL-17A and PGN in either cell line (Fig. 2C) . To exclude the possibility that effect of IL-17A is only observed in cell lines, the effect of IL-17A on the IL-8 gene expression was evaluated in NHBE and DHBE-CF cells. A low of IL-8 gene induction and no synergy was observed when IL-17A and PGN were used together for IL-8 induction in NHBE cells. However, there was significant synergy in IL-8 gene and protein induction in DHBE-CF cells when IL-17A and PGN were used together ( Fig. 2: D and E) .
The effect of IL-17A co-treatment with a Gram-negative bacterial LPS was then assessed and showed a significant synergistic induction of IL-8 gene and protein observed with the combined exposure to IL-17A and LPS, a TLR4 agonist (Fig. 3: A and B) . Moreover, no synergy was observed when the IL-17A and LPS combination was used to treat the non-CF cell lines, 16HBE14o-and Calu-3 cells (Fig. 3C) . As was observed in the primary cells treated with PGN, the expression of IL-8 by co-treatment with IL-17A and LPS was dramatically higher in DHBE-CF cells when compared to that in NHBE cells (Fig. 3: D and E) . Taken together, these data suggest an immunostimulatory role for IL-17A during bacterial infection of CF airway.
p38 MAPK activation is involved in the synergistic induction of IL-8 in CF cells
While having demonstrated the synergy between IL- were normalized to 18s ribosomal RNA (internal control). B: CFBE41o-cells were stimulated with IL-17A (1, 10, 100 ng/ml) for 36 h and then analyzed by ELISA to determine the IL-8 protein levels in conditioned media. C: CFBE41o-cells were stimulated with IL-17A (100 ng/ml) at the indicated times and then lysed in sample buffer. IκBα and MAPK phosphorylation was assessed by western blotting. D) CFBE41o-cells were pretreated with 10 μM SB203580 (p38 pathway inhibitor), 10 μM PD98059 (ERK pathway inhibitor), 10 μM SP600125 (JNK pathway inhibitor), or vehicle control (DMSO) before a 4-h treatment with IL-17A (100 ng/ml). Real-time Q-PCR was then performed to quantify IL-8 mRNA levels. In both the Q-PCR and ELISA analyses, results represent the mean ± S.D. from three independent experiments. ANOVA using the TukeyKramer procedure was used to identify the differences of cytokines expression among the groups indicated in the figure (**P < 0.005, ***P < 0.0005; n.s., not significant).
17A and PGN or LPS in promoting IL-8 expression in CF cells, the mechanisms that underlie IL-17A-based synergy is still undefined. Initial studies evaluating the role of TLR2 and TLR4 expression in the IL-17A-based synergistic increases in PGN-or LPS-dependent IL-8 induction showed that neither TLR2 nor TLR4 gene expression was affected by IL-17A treatment (Fig. 4) . Analysis of intracellular signaling pathways activated by IL-17A treatment was assessed in CFBE41o-cells (Fig. 1C) . PGN and LPS phosphorylate IκBα, p38, and JNK, while IL-17A phosphorylates p38 and ERK (Fig.  5: A and B) . When the cells were co-treated with PGN or LPS and IL-17A, only p38 phosphorylation was significantly increased (Fig. 5: A -C) . The role of p38 in the IL-17A-mediated synergistic effect on PGN-or LPSdependent IL-8 induction was evaluated by treating CFBE41o-cells with anisomycin, a p38 MAPK agonist (29) . As shown in Fig. 5D , anisomycin strongly phosphorylates p38 MAPK in CFBE41o-cells. This increase in p38 MAPK phosphorylation was accompanied by a concomitant increase of IL-8 expression upon co-treatment with PGN or LPS (Fig. 5E ) and implies that IL-17A modulation of p38 MAPK may be responsible for the synergistic increase in IL-8 expression in CF cells. Although a previous study showed increased IL-8 mRNA stability by IL-17A through TNFα-related mechanism (30), it is unlikely that the IL-17A-mediated synergy observed here is caused by enhanced IL-8 mRNA stabil- . B: CFBE41o-cells were treated with PGN (1 μg/ml) alone or in combination with IL-17A (100 ng/ml) for 24 h and then analyzed by ELISA to determine IL-8 protein levels in conditioned media. C: 16HBE14o-and Calu-3 were treated with PGN (1 μg/ml) alone or in combination with IL-17A (100 ng/ml) for 4 h, followed by IL-8 mRNA Q-PCR analysis. D: Primary NHBE and DHBE-CF cells were treated with PGN (1 μg/ml) alone or in combination with IL-17A (100 ng/ml) for 4 h, followed by Q-PCR analysis to determine the level of IL-8 mRNA expression. E: Primary DHBE-CF cells were treated with PGN (1 μg/ml) alone or in combination with IL-17A (100 ng/ml) for 48 h, followed by IL-8 protein ELISA analysis. Results represent the mean ± S.D. from three independent experiments. ANOVA using the Tukey-Kramer protocol was implemented to identify the differences between the expression of PGN-treated and PGN / IL-17A-treated CFBE41o-, NHBE, and DHBE-CF cells (*P < 0.05, **P < 0.005, ***P < 0.0005; n.s., not significant).
ity, since treatment of cells with actinomycin D, an RNA synthesis inhibitor, had no effect on the expression of IL-8 in PGN-or LPS-co-treated with IL-17A over 180 min under incubation with actinomycin D (Fig. 5F ). were normalized to the level of 18s ribosomal RNA (internal control). B: CFBE41o-cells were treated with LPS (10 μg/ml) alone or in combination with IL-17A (100 ng/ml) for 24 h, and then IL-8 protein levels in conditioned media were determined by ELISA analysis. C: 16HBE14o-and Calu-3 were treated with LPS (10 μg/ml) alone or in combination with IL-17A (100 ng/ml) for 4 h, followed by Q-PCR. D: Primary NHBE and DHBE-CF cells were treated with LPS (10 μg/ml) alone or in combination with IL-17A (100 ng/ml) for 4 h and then analyzed by Q-PCR. E: Primary DHBE-CF cells were treated with LPS (10 μg/ml) alone or in combination with IL-17A (100 ng/ml) for 48 h. IL-8 protein levels in condition media were then determined by ELISA analysis. Results represent the mean ± S.D. from three independent experiments. ANOVA using the Tukey-Kramer protocol was implemented to assess the significance of the differences in expression between LPS-treated and LPS / IL-17A-treated CFBE41o-, NHBE, and DHBE-CF cells (*P < 0.05, **P < 0.005, ***P < 0.0005; n.s., not significant). 
Discussion
There has been an increasing interest on the biological activity of members of the IL-17 family, especially IL-17A, because of the diversity in its expression and its functional pleiotropism. Numerous pre-clinical and clinical studies identified IL-17A as a critical component in host defense responses and inflammatory diseases and suggest that IL-17A might be a promising therapeutic target (8 -10) . In CF, the elevated levels of IL-17A in the sputum of adult patients are thought to contribute to the bacterial infection related respiratory exacerbations that decrease with antibiotic therapy (6, 21, 22) . The results presented here are the first to indicate that IL-17A is a critical factor in the increase in IL-8 expression resulting from TLR2-and TLR4-dependent activation in CF airway. These studies are consistent with a previous clinical report showing that patients chronically infected with P. aeruginosa have higher IL-17A mRNA expression levels when compared to patients who were not chronically infected (21 (Fig.  5F ). Although the possibility that the mechanism may involve the enhanced activation of MKK3/6, an immediate upstream regulator of p38 MAPK in various types of signals as well as the IL-17A signal (31 -33) , with IL-17A co-treatment cannot be excluded. An interesting recent report by Valente et al., relevant to the studies presented here, showed that a unique signaling molecule MAPK phosphatase-1 (MKP-1), a negative regulator of p38 MAPK, is down-regulated by IL-17A in adult mouse primary cardiac fibroblast (34) . This suggests that IL-17A-dependent MKP-1 suppression will contribute to the enhanced p38 MAPK signaling. In the context of the studies presented here, one can envision a mechanism where IL-17A-mediated inhbition of MKP-1 contributes to the synergism between IL-17A and TLR2/4 signals by enhnacing phosphorylation of p38 MAPK in CF airway epithelial cells.
While it is still unclear whether TLR2 and TLR4 signaling pathways are solely responsible for modulating inflamation in CF airways, IL-17A has been shown to prime CF airway epithelial cells (Cufi cells) to increase IL-8 expression in response to bacterial infection through the up-regulation of one of the pattern recognition receptors (PRRs), NOD1 (23) . Furthermore, there are numerous reports that demonstrate IL-17A synergistic enhancement of pro-inflammatory responses when in combination with other cytokines such as TNFα, IL-1β, and interferon-γ (11) that are associated with inflammation in CF (35) . Thus, there may be other inflammatory signaling pathways that can be modulated by IL-17A. Further study will be important to disect the mechanisms whereby IL-17A enhances CF airway inflammatory pathogenesis.
Whether p38 MAPK can be a potential therapeutic target in CF is an important issue that will require further study. Increasing evidence suggests that the p38 MAPK signal is activated by various pro-inflammatory and stress-related stimuli under abnormal pulmonary conditions such as asthma, COPD, and CF (36, 37) . Since p38 MAPK up-regulates the expression of factors that are critically involved in the pathogenesis of these pulmonary diseases such as inflammatory cytokines, mucins (38) , proteases (39) , and reactive oxygen species (3), it is a plausible therapeutic target for the treatment of CF. Clearly, further study using in vivo models is necessary to evaluate the potential of targeting IL-17A or p38 for the treatment of CF airway inflammation. The data from the present study suggest that IL-17A is a critical factor in increasing IL-8 expression in bacteria-infected CF airway possibly via p38 MAPK activation.
